1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Cell Design Labs Envisions Robot Control of Tomorrow's CAR-T Therapies

 
• By Emily Hayes

Emerging Company Profile: San Francisco startup aligned with Kite Pharma believes T-cells may be programmed to reversibly activate and deactivate, greatly improving specificity, efficacy and safety of chimeric antigen receptor T-cell therapies.

Using a deal with CAR-T frontrunner Kite Pharma Inc. as a springboard, San Francisco-based start-up Cell Design Labs hopes to bring forward a new generation of specific, reversible T-cell therapies as an alternative to the imprecise, explosive nature of the candidates tested to date.

Kite Pharma, Juno Therapeutics Inc. and Novartis AG have been at the forefront of development for chimeric antigen...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Maraganore, Meanwell Launch Corsera, Their Third Act In Cardiovascular Disease

 
• By Mandy Jackson

The biopharma industry veterans John Maraganore and Clive Meanwell partnered successfully twice before. With Corsera, the co-CEOs have raised more than $50m and aim to predict and prevent cardiovascular disease.

Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals

 
• By Andrew McConaghie

Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.

More from Business

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By Kevin Grogan

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

Biogen Showcases Lupus Pipeline But Investors Will Have To Wait For Data

 
• By Jessica Merrill

R&D leaders highlighted two potential first-in-class assets during a therapeutic area overview, but regulatory filings remain years out.